Marchesani F, Rizzo S, Salvini P
Minerva Med. 1981 Feb 28;72(7):401-8.
An open clinical trial was run on the therapeutic efficacy of a new balsamic-antiinflammatory molecule, guacetisal (presented as 500 mg Broncaspin capsules). The drug was given for a minimum of 7 days to 45 male and female patients with an average age of 64 yr suffering from variously serious diseases of the airways. The concomitant administration of fluidifying, balsamic, steroid, antipyretic and anti-inflammatory drugs was avoided, whereas various combinations of cardiokinetics, diuretics, theophyllines, and antibiotics were used where required. Clinical assessment of the parameters chosen pointed to the good therapeutic activity of the preparation, which is specifically indicated in inflammatory conditions of the airways, especially chronic forms subject to periodic recrudescence. Its equally good tolerability serves to make guacetisal extremely easy to use, with the results that its employment in non-specialist environments can also be recommended.
对一种新型香脂抗炎分子瓜西他柳（以500毫克的Broncaspin胶囊形式呈现）的治疗效果进行了一项开放性临床试验。该药物给予了45名平均年龄为64岁、患有各种严重气道疾病的男性和女性患者，疗程至少7天。避免同时使用化痰、香脂、类固醇、退烧药和消炎药，而在需要时使用了各种强心剂、利尿剂、茶碱和抗生素的组合。对所选参数的临床评估表明该制剂具有良好的治疗活性，特别适用于气道的炎症状况，尤其是易周期性复发的慢性形式。其同样良好的耐受性使得瓜西他柳极易使用，因此也可推荐在非专业环境中使用。
